Atsena Therapeutics Announces Oversubscribed $150 Million Series C Financing To Further Advance Ocular Gene Therapy Programs
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on reversing or preventing blindness, announced the successful close of an oversubscribed $150 million Series C financing round.
Genascence Announces Six-Month Results From Phase 1b DONATELLO Trial Indicating GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms
UF startup Genascence Corporation, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, announced positive interim safety and biomarker results from the Phase 1b DONATELLO clinical trial evaluating GNSC-001.
Atsena Therapeutics Announces Dosing Completed in Part A of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 To Treat X-Linked Retinoschisis
UF startup Atsena Therapeutics announced dosing has been completed in Part A of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
How Atsena Got Its Gene Therapy To Spread Subretinally To Treat XLRS
UF researcher Sanford Boye, co-founder and adviser of UF Startup Atsena Therapeutics, shared insights into how the company developed its gene therapy to achieve subretinal spread for treating XLRS.
Novartis Buys Kate Therapeutics, Eyeing $55B CGT Market Opportunity by 2030
UF Startup Kate Therapeutics, a gene therapy specialist, is being acquired by Novartis in a deal worth up to $1.1 billion. This acquisition aligns with Novartis’s efforts to deliver treatments for neuromuscular disorders and fits into the pharma’s strategy to expand its new modality pipeline, ensuring long-term business sustainability.
Genascence Granted FDA Fast Track Designation for GNSC-001 in Patients With Osteoarthritis (OA) of the Knee
UF Startup Genascence Corporation announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) for GNSC-001, a potential first-in-class gene therapy for the treatment of patients with osteoarthritis (OA) of the knee.
Kriya Highlights Positive Preclinical Data for KRIYA-586, a Gene Therapy Product Candidate for Thyroid Eye Disease (TED), at ESOPRS Annual Meeting
UF Startup Kriya Therapeutics, a biopharmaceutical company developing gene therapies, announced preclinical data from its gene therapy program for thyroid eye disease (TED).
Gene Therapy Restores Vision in First-Ever Trial for Rare, Inherited Blindness
A gene therapy developed by University of Florida scientists, which restored useful vision to most patients with the rare, inherited blindness known as Leber congenital amaurosis type I, or LCA1, in a small trial.
Atsena Therapeutics Receives Rare Pediatric Disease Designation From the U.S. FDA for ATSN-201 Gene Therapy To Treat X-Linked Retinoschisis
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation (RPD) for ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
JPMorgan Upgrades Solid Biosciences Stock, Sees Growth Potential
JPMorgan upgraded Solid Biosciences stock, a biotechnology company that acquired UF startup AavantiBio, from Neutral to Overweight, and increased the price target to $15.00 from the previous $10.00. The firm's decision reflects a positive outlook on the company's prospects, particularly with upcoming developments expected in the fourth quarter.
